Hermansky-Pudlak syndrome with early onset inflammatory bowel disease due to loss of dysbindin expression

Eur J Med Genet. 2023 Jul;66(7):104786. doi: 10.1016/j.ejmg.2023.104786. Epub 2023 May 11.

Abstract

Hermansky-Pudlak syndrome (HPS) is a heterogeneous group of autosomal recessive genetic disorders characterized by oculocutaneous albinism, bleeding diathesis, and variable presentation of immune deficiency and dysregulation. The pathogenesis of HPS involves mutations in genes responsible for biogenesis and trafficking of lysosome-related organelles, essential for the function of melanosomes, platelet granules, and immune cell granules. Eleven genes coding for proteins in the BLOC-1, BLOC-2, BLOC-3 and AP-3 complexes have been implicated in the pathogenesis of HPS. To date, the rare subtype HPS-7 associated with bi-allelic mutations in DTNBP1 (dysbindin) has only been reported in 9 patients. We report a novel DTNBP1 splicing mutation in a 15-month-old patient with HPS-7 phenotype and severe inflammatory bowel disease (IBD). This patient's leukocytes have undetectable dysbindin protein. We also identify dysregulated expression of several genes involved in activation of the adaptive immune response. This case underscores the emerging immunological consequences of dysbindin deficiency and suggests that DTNBP1 mutations may underlie some rare cases of very early onset IBD.

Keywords: DTNBP1; Dysbindin; HPS-7; Hermansky-Pudlak syndrome; Oculocutaneous albinism; Very early onset IBD.

MeSH terms

  • Carrier Proteins / genetics
  • Carrier Proteins / metabolism
  • Dysbindin / genetics
  • Dysbindin / metabolism
  • Hermanski-Pudlak Syndrome* / genetics
  • Hermanski-Pudlak Syndrome* / pathology
  • Humans
  • Inflammatory Bowel Diseases* / complications
  • Inflammatory Bowel Diseases* / genetics
  • Mutation
  • Proteins / genetics

Substances

  • Carrier Proteins
  • Dysbindin
  • Proteins
  • DTNBP1 protein, human